Bayer HealthCare of Berlin has entered into a strategic agreement to transfer its hematological oncology portfolio to Genzyme Corp. of Cambridge, Mass. This includes granting the American company exclusive worldwide licenses for several of the products in the portfolio. In return, the German company will receive milestone payments and royalties, which could add up to as much as $650 million.